Vifor Pharma


Robust finish to FY18; mid-term financial targets within reach

15/03/19 -"Vifor reported strong FY18 results with revenue as well profits exceeding the already raised targets – driven by Ferinject, Veltassa and VFMCRP. The positive growth momentum is likely to continue in ..."

Pages
50
Language
English
Published on
15/03/19
You may also be interested by these reports :
20/05/19
Given the robust oncology, neuroscience and rare disease portfolio, the financial targets for FY22 seem attainable in our view. Somatuline, despite ...

20/05/19
2018 EPS came in higher than our expectations due to a lower effective tax rate than expected.

20/05/19
Hikma maintains FY 19 guidance in the Q1 trading update. Not much is disclosed in the trading update, but guidance implies 0-4% growth for FY 19.

16/05/19
Faes Farma’s strong performance was attributable to the solid performance in the domestic markets, along with the continued demand for Bilastine ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO